非那雄胺治疗良性前列腺增生并发血尿的Meta分析

目的:系统评价非那雄胺治疗良性前列腺增生(BPH)并发血尿的有效性。方法:电子检索MED-LINE(1966年12月至2009年4月)、EMBASE(1974年12月至2009年4月)、Cochrane图书馆(2009年第1期)和中国期刊全文数据库(1994年12月至2009年4月)、中文科技期刊全文数据库(1989年12月至2009年4月)、中国生物医学文献数据库(1978年12月至2009年4月),并手工检索相关杂志。纳入相关的随机对照试验(RCT),由至少两位系统评价员独立进行文献筛查和质量评价,分歧通过讨论解决,采用RevMan5.0软件进行Meta分析。结果:Meta分析结果显示:12个月后与安慰剂组比较,非那雄胺组的血尿发生率明显降低(OR0.11,95%CI:0.06～0.21),有显著性差异(P<0.05)。结论:非那雄胺对BPH并发血尿有良好的治疗及预防作用。建议大样本、多中心、设计良好的RCT,提供更佳循证医学依据。

Effects of finasteride on hematuria associated with benign prostatic hyperplasia:A Meta-analysis

Objective :To systematically evaluate the effects of finasteride on hematuria associated with benign prostatic hyperplasia (BPH). Methods :We electronically searched MEDLINE (December 1966-April 2009),EMBASE (December 1974-April 2009),The Cochrane Library (Issue 1,2009),CNKI (December 1994-April 2009),VIP (December 1989-April 2009) and CBM (December 1978-April 2009),and handsearched several relevant journals as well. Randomized controlled trials were assessed with the methods recommended by the Cochrane Collaboration. The data were screened and systematically analyzed by at least two reviewers independently using the RevMan 5.0 software. Results :Compared with the placebo control group,the finasteride group showed a significantly decreased incidence of hematuria during the 12 months follow-up period (OR 0.11,95% CI:0.06-0.21,P<0.05). Conclusion :Finasteride has desirable therapeutic and preventive effects on BPH-associated hematuria. More well-designed multicentered randomized controlled trials of large sample size are invited to provide further evidence for this conclusion.